Anti-transforming growth factor-β therapy in patients with myelofibrosis

Leuk Lymphoma. 2014 Feb;55(2):450-2. doi: 10.3109/10428194.2013.805329. Epub 2013 Jun 24.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Exanthema / chemically induced
  • Fatigue / chemically induced
  • Female
  • Humans
  • Male
  • Middle Aged
  • Primary Myelofibrosis / drug therapy*
  • Transforming Growth Factor beta / antagonists & inhibitors*
  • Transforming Growth Factor beta / immunology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Transforming Growth Factor beta
  • fresolimumab

Associated data

  • ClinicalTrials.gov/NCT01291784